Assessing Functional Outcomes of Partial Versus Radical Nephrectomy for T1b-T2 Renal Masses: Results from a Multi-institutional Collaboration.

Acute kidney injury Creatinine Long-term functional outcomes Partial nephrectomy Radical nephrectomy Renal function

Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 25 01 2024
accepted: 28 03 2024
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 27 5 2024
Statut: aheadofprint

Résumé

Deterioration of renal function is associated with increased all-cause mortality. In renal masses larger than 4 cm, whether partial versus radical nephrectomy (PN vs. RN) might affect long-term functional outcomes is unknown. This study tested the association between PN versus RN and postoperative acute kidney injury (AKI), recovery of at least 90% of the preoperative estimated glomerular filtration rate (eGFR) at 1 year, upstaging of chronic kidney disease (CKD) one stage or more at 1 year, and eGFR decline of 45 ml/min/1.73 m Data from 23 high-volume institutions were used. The study included only surgically treated patients with single, unilateral, localized, clinical T1b-2 renal masses. Multivariable logistic regression analyses were performed. Overall, 968 PN patients and 325 RN patients were identified. The rate of AKI was lower in the PN versus the RN patients (17% vs. 58%; p < 0.001). At 1 year after surgery, for the PN versus the RN patients, the rate for recovery of at least 90% of baseline eGFR was 51% versus 16%, the rate of CKD progression of ≥ 1 stage was 38% versus 65%, and the rate of eGFR decline of 45 ml/min/1.73 m For cT1b-2 masses, RN portends worse immediate and 1-year functional outcomes. When technically feasible and oncologically safe, efforts should be made to spare the kidney in case of large renal masses to avoid the hazard of glomerular function loss-related mortality.

Sections du résumé

BACKGROUND BACKGROUND
Deterioration of renal function is associated with increased all-cause mortality. In renal masses larger than 4 cm, whether partial versus radical nephrectomy (PN vs. RN) might affect long-term functional outcomes is unknown. This study tested the association between PN versus RN and postoperative acute kidney injury (AKI), recovery of at least 90% of the preoperative estimated glomerular filtration rate (eGFR) at 1 year, upstaging of chronic kidney disease (CKD) one stage or more at 1 year, and eGFR decline of 45 ml/min/1.73 m
METHODS METHODS
Data from 23 high-volume institutions were used. The study included only surgically treated patients with single, unilateral, localized, clinical T1b-2 renal masses. Multivariable logistic regression analyses were performed.
RESULTS RESULTS
Overall, 968 PN patients and 325 RN patients were identified. The rate of AKI was lower in the PN versus the RN patients (17% vs. 58%; p < 0.001). At 1 year after surgery, for the PN versus the RN patients, the rate for recovery of at least 90% of baseline eGFR was 51% versus 16%, the rate of CKD progression of ≥ 1 stage was 38% versus 65%, and the rate of eGFR decline of 45 ml/min/1.73 m
CONCLUSIONS CONCLUSIONS
For cT1b-2 masses, RN portends worse immediate and 1-year functional outcomes. When technically feasible and oncologically safe, efforts should be made to spare the kidney in case of large renal masses to avoid the hazard of glomerular function loss-related mortality.

Identifiants

pubmed: 38802714
doi: 10.1245/s10434-024-15305-w
pii: 10.1245/s10434-024-15305-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Society of Surgical Oncology.

Références

Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
doi: 10.1056/NEJMoa041031 pubmed: 15385656
Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59:543–52.
doi: 10.1016/j.eururo.2010.12.013 pubmed: 21186077
MacLennan S, Imamura M, Lapitan MC, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol. 2012;62:1097–117.
doi: 10.1016/j.eururo.2012.07.028 pubmed: 22841673
Capitanio U, Terrone C, Antonelli A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a–T1b renal mass and normal preoperative renal function. Eur Urol. 2015;67:683–9.
doi: 10.1016/j.eururo.2014.09.027 pubmed: 25282367
Scosyrev E, Messing EM, Sylvester R, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol. 2014;65:372–7.
doi: 10.1016/j.eururo.2013.06.044 pubmed: 23850254
Mir MC, Derweesh I, Porpiglia F, et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2017;71:606–17.
doi: 10.1016/j.eururo.2016.08.060 pubmed: 27614693
Ching CB, Lane BR, Campbell SC, et al. Five- to 10-year follow-up of open partial nephrectomy in a solitary kidney. J Urol. 2013;190:470–4.
doi: 10.1016/j.juro.2013.03.028 pubmed: 23499747
Lee HJ, Liss MA, Derweesh IH. Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors. Curr Opin Urol. 2014;24:448–52.
doi: 10.1097/MOU.0000000000000081 pubmed: 24921904
Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–57.
doi: 10.1038/nrneph.2017.2 pubmed: 28239173
Bravi CA, Vertosick E, Benfante N, et al. Impact of acute kidney injury and its duration on long-term renal function after partial nephrectomy. Eur Urol. 2019;76:398–403.
doi: 10.1016/j.eururo.2019.04.040 pubmed: 31080127 pmcid: 7641193
Ochoa-Arvizo M, García-Campa M, Santos-Santillana KM, et al. Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis. Urol Oncol. 2023;41:113–24.
doi: 10.1016/j.urolonc.2022.11.024 pubmed: 36642639
Lane BR, Demirjian S, Derweesh IH, et al. Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate. Eur Urol. 2015;68:996–1003.
doi: 10.1016/j.eururo.2015.04.043 pubmed: 26012710
Assel M, Sjoberg D, Elders A, et al. Guidelines for reporting of statistics for clinical research in urology. Eur Urol. 2019;75:358–67.
doi: 10.1016/j.eururo.2018.12.014 pubmed: 30580902
Panageas KS, Schrag D, Riedel E, et al. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med. 2003. https://doi.org/10.7326/0003-4819-139-8-200310210-00009 .
doi: 10.7326/0003-4819-139-8-200310210-00009 pubmed: 14568854
R: The R Project for Statistical Computing. Retrieved 14 Apr 2022 at https://www.r-project.org/ .
Volpe A, Amparore D, Mottrie A. Treatment outcomes of partial nephrectomy for T1b tumours. Curr Opin Urol. 2013;23:403–10.
doi: 10.1097/MOU.0b013e328363a5c0 pubmed: 23907503
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.
doi: 10.1038/ki.2011.379 pubmed: 22113526
Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43:855–66.
doi: 10.1007/s00134-017-4809-x pubmed: 28466146 pmcid: 5487594
The PARTIAL study: a randomised trial of the clinical and cost effectiveness of partial vs radical nephrectomy for clinically localised renal cell carcinoma. NIHR Funding and Awards. Retrieved 12 Aug 2023 at https://fundingawards.nihr.ac.uk/award/NIHR133561 .
Karellas ME, Obrien MF, Jang TL, et al. Partial nephrectomy for selected renal cortical tumours of ≥ 7 cm. BJU Int. 2010;106:1484–7.
doi: 10.1111/j.1464-410X.2010.09405.x pubmed: 20518765 pmcid: 4319322
Peycelon M, Hupertan V, Comperat E, et al. Long-term outcomes after nephron-sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. 2009;181:35–41.
doi: 10.1016/j.juro.2008.09.025 pubmed: 19012929
Bravi CA, Larcher A, Capitanio U, et al. Perioperative outcomes of open, laparoscopic, and robotic partial nephrectomy: a prospective multicenter observational study (The RECORd 2 Project). Eur Urol Focus. 2021;7:390–6.
doi: 10.1016/j.euf.2019.10.013 pubmed: 31727523

Auteurs

Stefano Tappero (S)

IRCCS Ospedale Policlinico San Martino, Genova, Italy. stefano.m.tappero@gmail.com.
Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy. stefano.m.tappero@gmail.com.
Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. stefano.m.tappero@gmail.com.

Carlo Andrea Bravi (CA)

Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK.
Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Zine Eddine Khene (ZE)

Department of Urology, University of Rennes, Rennes, France.

Riccardo Campi (R)

Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Angela Pecoraro (A)

Department of Urology, Hospital Pederzoli, Peschiera del Garda, Verona, Italy.

Pietro Diana (P)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.

Chiara Re (C)

Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
ASST-Sette Laghi, Circolo and Fondazione Macchi Hospital, University of Insubria, Varese, Italy.

Carlo Giulioni (C)

Unit of Urology, Jesi Hospital, Jesi, Ancona, Italy.
Department of Urology, Polytechnic University of Marche Region, Ancona, Italy.

Alp T Beksac (AT)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Riccardo Bertolo (R)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Tarek Ajami (T)

Department of Urology, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Kennedy E Okhawere (KE)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Margaret Meagher (M)

University of California, San Diego, La Jolla, CA, USA.

Arman Alimohammadi (A)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Carlo Terrone (C)

IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.

Andrea Mari (A)

Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Clinical and Experimental Medicine, Careggi Hospital, University of Florence, Florence, Italy.

Daniele Amparore (D)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Luigi Da Pozzo (L)

ASST Papa Giovanni XXIII, Bergamo, Italy.
School of Medicine, University of Milano-Bicocca, Milan, Italy.

Umberto Anceschi (U)

Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Nazareno Suardi (N)

Department of Urology, University of Brescia, Brescia, Italy.

Antonio Galfano (A)

Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Alessandro Larcher (A)

Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Riccardo Schiavina (R)

Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Erdem Canda (E)

Department of Urology, Koç University Hospital, Istanbul, Turkey.
RMK AIMES, Rahmi M. Koç Academy of Interventional Medicine, Education, and Simulation, Istanbul, Turkey.

Xu Zhang (X)

Department of Urology, Chinese PLA General Hospital, Beijing, China.

Shahrokh Shariat (S)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Francesco Porpiglia (F)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Alessandro Antonelli (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Ketan Badani (K)

Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Ithaar Derweesh (I)

University of California, San Diego, La Jolla, CA, USA.

Alberto Breda (A)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.

Alexander Mottrie (A)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Paolo Dell'Oglio (P)

Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Urology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.

Classifications MeSH